Sumary of WHO’s take on remdesivir leads to more confusion over coronavirus drugs:
- Health officials around the world are clashing over the use of certain drugs for COVID-19, leading to different treatment options for patients depending on where they live..
- On Friday, a World Health Organization guidelines panel advised against using the antiviral remdesivir for hospitalized patients, saying there no evidence it improves survival or avoids the need for breathing machines..
- Within the U.S., a federal guidelines panel and some leading medical groups have not endorsed two other therapies the Food and Drug Administration authorized for emergency use — Eli Lilly experimental antibody drug and convalescent plasma, the blood of COVID-19 survivors..
- Until the National Institutes of Health guidelines endorse a treatment, “I’m really reluctant … to call that standard of care.”.
- “It not unusual for professional guidelines to disagree with each other, it just that it all under the microscope with COVID-19,”.
- The WHO guidelines stress that the drug does not save lives, based heavily on a WHO-sponsored study that was larger but much less rigorous than the U.S.-led one that found it had other benefits..
- Gilead charges $3,120 for a typical treatment course for patients with private insurance and $2,340 for people covered by government health programs in the U.S….